Table 1 Comparison between group I and group II as regards autoimmune markers, treatment, and SLEDAI score
From: Electroencephalography in systemic lupus erythematosus patients with neuropsychiatric manifestations
| Â | Group I, no. (%) | Group II, no. (%) | P value | Sig. |
|---|---|---|---|---|
Consumed C3 | 11 (36.7%) | 11 (36.7%) | 1.000 | NS |
Consumed C4 | 11 (36.7%) | 11 (36.7%) | 1.000 | NS |
LAC | 7 (23.3%) | 14 (46.7%) | 0.058 | NS |
ACL IgG | 6 (20%) | 13 (43.3%) | 0.052 | NS |
ACL IgM | 5 (16.7%) | 12 (40%) | 0.045 | S |
Steroids | 8 (26.7) | 9) 30.0( | 0.774 | NS |
Hydroxychloroquin | 8 (26.7) | 14 )46.7( | 0.108 | NS |
Azathioprine | 16 (53.3) | 15 )50.0( | 0.796 | NS |
Cyclophosphamide | 23 (76.7) | 23 )76.7 | 1.000 | NS |
MMF | 25 (83.3) | 29 )96.7( | 0.085 | NS |
SLEDAI Median (IQR) Range | 4 (0–8) | 16 (12–24) | 0.000 | HS |
No activity (0) | 0–28 | 8–38 | 0.002 | HS |
Mild activity (1–5) | 8 (26.7%) | 0 (0.0%) | 0.001 | HS |
Moderate activity (6-10) | 9 (30.0%) | 0 (0.0%) | 0.542 | NS |
High activity (11–19) | 8 (26.7%) | 6 (20.0%) | 0.001 | HS |
Very high activity (≥ 20) | 2 (6.7%) | 13 (43.3%) | 0.015 | S |